momentum set vertex solid year share
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
methodolog valu compani
vertex momentum first quarter strongli posit
firm meet full-year expect
increas fair valu estim firm per
share reflect time valu money
margin optimist sale expect kalydeco
believ vertex share still leeway upsid
market may underestim vertex pipelin portfolio
beyond cystic fibrosi view
modest probability-weight sale contribut
compani non-cf pipelin asset given early-stag
natur believ vertex defens cystic fibrosi
powerhous give firm high margin development
misstep form basi narrow econom moat
approv launch symdeko next-gener
orkambi cystic fibrosi patient two copi
mutat coupl steadi growth
kalydeco drove top-lin sale quarter kalydeco
monotherapi larg satur cystic fibrosi
popul gate mutat although growth appear
ever-so-slightli robust previou
forecast expect symdeko higher efficaci
fewer safeti issu orkambi expand
homozyg cf popul vertex drug name
captur patient discontinu orkambi never
start treatment uptak symdeko
anticip cannib orkambi sale expect
continu reimburs agreement european market
approv pediatr patient partial off-set
declin near term symdeko approv europ
anticip second half year would
acceler drug launch
next-largest commerci driver vertex approv
cf patient minim cftr protein function mutat
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko cystic fibrosi addit sever mid- late-stag
product target market vertex success develop
commerci two hiv proteas inhibitor outlicens
glaxosmithklin vertex pipelin also includ therapi treatment
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
well way compani move forward pivot
test two tripl combin regimen one program
featur corrector
patient enrol on-going model anticip
launch addit next-gener corrector
also develop development progress
once-daili potenti deuter version
kalydeco twice-daili drug believ vertex cystic
pipelin
competitor food drug administr
request dose-rang data
candid progress pivot test push
timelin launch once-daili drug howev
updat time affect valuat
believ success would rais barrier entri
competitor would contribut increment sale
well-defend
introduct gene therapi remain medium-
term threat vertex partnership rna
therapi crispr gene therapi high
bar set vertex drug segment cystic
fibrosi popul reason mitig risk
view movement vertex non-cf portfolio first
quarter -- includ posit proof-of-concept data
acut pain permiss advanc gene therapi drug
clinic studi b-thalassemia crispr
therapeut -- also contribut posit moat trend
rate vertex given compani ampl cash hand
manag team strong experi cystic
fibrosi confid vertex abil pivot
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
